Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: Living Drugs adds to the canon of inspiring science documentaries
Michel Sadelain is the 2024 Gairdner International Award laureate, along with Dr. Zelig Eshhar, for his “seminal contributions to the conception, development and application of CD19-CAR T cell therapy for cancer.” It’s been a good year for Dr. Sadelain, who also won the 2024 Breakthrough Prize in Life Sciences. See the full list of his […]
Right Turn: Summer 2024 viewing for stem cell and RM fans
He’s back! The regenerative medicine (RM) field’s unofficial mascot – Deadpool – is back in theatres and all over media and social media due to what one must assume is a super(hero)-sized marketing budget. Although some may disagree on his status as a mascot, you can’t ignore his regenerative abilities. Wade Wilson, aka Deadpool, can […]
Blog carnival: Are we peering through rose-coloured glasses at the cell therapy investment landscape?
This has never happened before. In eight years of hosting the blog carnival, we have never encountered a situation where the conclusions have been so similar. Given this year’s topic, the optimism is a good thing. So here is our topic: Venture financing in cell therapies was at a record high in 2020 and 2021, […]